<DOC>
	<DOCNO>NCT00370825</DOCNO>
	<brief_summary>The investigator use sequential design combine miltefosine AmBisome different dos .</brief_summary>
	<brief_title>Combination Chemotherapy Treatment Indian Kala-Azar</brief_title>
	<detailed_description>In sequential design four arm study one arm reference arm three arm consist initial dose liposomal amphotericin B first day follow miltefosine . Both drug use different dos . Reference arm consist single dose amBisome 5 mg/kg . After end treatment , post treatment assessment do day 16 ( initial cure ) six month ( final cure ) . Safety parameter evaluate day 0 , 8 16 . An arm efficacy le 75 % close . There periodical assessment study result completion 5 patient arm .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<criteria>Clinical diagnosis active VL consistent sign symptom ( e.g. , fever , splenomegaly ) . Confirmed diagnosis bonemarrow splenic aspirate smear show characteristic amastigotes . Male female . Ages 12 65 year . Both newly diagnose case patient receive previous treatment ( latter case 2week washout require start study treatment ) . WBC &gt; 1,000/mm3 . Hemoglobin ≥ 4 g/dL Pregnancy breastfeeding . HIV positive serology . ASAT , ALAT , AP ≥ 3 time upper limit normal range . Bilirubin ≥ 2 time upper limit normal range . Prothrombin time ≥ 5 second control . Serum creatinine BUN ≥ 1.5 time upper limit normal range . Any medical condition situation compromise compliance study procedure . HIV</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Visceral leishmaniasis</keyword>
	<keyword>miltefosine</keyword>
	<keyword>AmBisome</keyword>
	<keyword>Combination</keyword>
</DOC>